Skip to main content

Featured Review: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization

Recently, the focus of enhancing tumor radiosensitivity has shifted from chemotherapeutics to targeted therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are a novel class of selective cell cycle therapeutics that target the cyclin D-CDK4/6 complex and induce G1 phase arrest. These agents have demonstrated favorable effects when used as monotherapy or combined with endocrine therapy and targeted inhibitors, stimulating further explorations of other combination strategies. Multiple preclinical studies have indicated that CDK4/6 inhibitors exhibit a synergistic effect with radiotherapy both in vitro and in vivo. The principal mechanisms of radiosensitization effects include inhibition of DNA damage repair, enhancement of apoptosis, and blockade of cell cycle progression, which provide the rationale for clinical use. CDK4/6 inhibitors also induce cellular senescence and promote anti-tumor immunity, which might represent potential mechanisms for radiosensitization. Several small sample clinical studies have preliminarily indicated that the combination of CDK4/6 inhibitors and radiotherapy exhibited well-tolerated toxicity and promising efficacy. However, most clinical trials in combined therapy remain in the recruitment stage. Further work is required to seek optimal radiotherapy-drug combinations. In this review, we describe the effects and underlying mechanisms of CDK4/6 inhibitors as a radiosensitizer and discuss previous clinical studies to evaluate the prospects and challenges of this combination.

Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

editorialjeccr@gmail.com

Articles

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Call for papers: Long non-coding and circular RNAs in the landscape of cancer progression and metastasis

lncRNA teaser image 2

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

The role of long non-coding and circular RNAs as potential cancer biomarkers.

The 2022 Special Issue will accept Research Articles and Reviews regarding the latest highlights on this topic. Submit here.

  • Submission opens: 1st January 2022
  • Submission deadline: 31st December 2022

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Call for Papers: Drugging cancer vulnerabilities toward innovative clinical trials

Drugging smallJournal of Experimental & Clinical Cancer Research is delighted to announce the new thematic series covering the actual knowledge of novel strategies on anticancer treatments.

The Special Issue will accept Research Articles and Reviews regarding the latest highlights on Drugging cancer vulnerabilities toward innovative clinical trials. Submit here.

  • Submission opens: 1st April 2021
  • Submission deadline: 31st December 2022

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Follow JECCR on Social Media

Social Media IconsTwitter

Facebook

LinkedIn

Follow JECCR's social media accounts to be kept up-to-date with the latest articles, collections and journal news!

Recognising Editorial Excellence

SN Editorial Excellence badgeJournal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

Reviewer Acknowledgement and New Recruitment

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to editorialjeccr@gmail.com

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

editorialjeccr@gmail.com


Annual Journal Metrics